Possible reprieve for failed Alzheimer’s drug
A month after Pfizer and Janssen’s Alzheimer’s drug bapineuzumab failed in a late-stage study, a new trial has found it may benefit a sub-group of patients.
Read MoreAuthor: Ben Adams
Jeremy Hunt to lead value-based pricing discussions
The new health secretary Jeremy Hunt will have a baptism of fire this month as he heads straight into negotiations over VBP.
Read MoreHunt replaces Lansley as UK health secretary
Andrew Lansley has been dropped as the UK health secretary just months after his controversial reform of the National Health Service became law.
Read MoreGrunenthal finally makes Thalidomide apology
More than half a century after Thalidomide caused serious disability to hundreds of children, Grunenthal, the manufacturer for the drug has now apologised for its disastrous side effects.
Read MoreFunding boost for NHS digital communication
The government will invest up to £99,000 for new projects that can help doctors and patients communicate digitally, whilst also increasing access to online information.
Read More- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
